Skip to main content

Marta Rodríguez Barranco

Institutions of which they are part

Research technician
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Marta Rodríguez Barranco

Institutions of which they are part

Research technician
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Caracterización de pacientes con esclerosis múltiple muy activa y evaluación del efecto de tratamientos de alta efectividad en la evolución de su enfermedad.

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Marta Rodríguez Barranco, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI22/01570
Duration: 01/01/2023 - 31/12/2025

SGR-Cat 2021: Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Ana Isabel Guerrero Perez, Carlos Nos Llopis, Sunny Malhotra Sareen, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Silvia Soler García, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Nuria Filló Papiol, Marta Rodríguez Barranco, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Javier Villacieros Álvarez, Rafael Garcia Merida, Maria Arantza Dema Etxezarreta, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 31/12/2024

Deciphering clinical features and pathogenesis of myelin oligodendrocyte glycoprotein (MOG) antibodies in adult patients with a first demyelinating syndrome

IP: Alvaro Cobo Calvo
Collaborators: Rosalia Horno Ocaña, Cristina Auger Acosta, Marta Rodríguez Barranco, Luciana Midaglia Fernandez, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI20/00800
Duration: 01/01/2021 - 30/06/2025

Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple

IP: Susana Otero Romero
Collaborators: Juliana Esperalba Esquerra, Mar Tintore Subirana, Laia Pinos Tella, Marta Rodríguez Barranco, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: Instituto de Salud Carlos III
Funding: 105270
Reference: PI19/01606
Duration: 01/01/2020 - 30/06/2024

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Cristina Gamez Cenzano

Cristina Gamez Cenzano

Senior researcher
Molecular Medical Imaging
Read more
Camille Guillard Sirieix

Camille Guillard Sirieix

Research technician
Neurodegenerative Diseases
Read more
Ferran Ramirez Viaplana

Ferran Ramirez Viaplana

Infectious Diseases
Read more
Mª Eulàlia Molinas Guilera

Mª Eulàlia Molinas Guilera

Tècnic/a Grau Superior
Academic Research Organisation (ARO)
Clinical Core Facilities
Core Facilities Area
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.